This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Toujeo-1-banner

TOUJEO®

insulin glargine 300 units/ml

Toujeo is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years 1

Prescribing Infomation can be found through the links in the Product Cards at the bottom of the page

Switching from GLP-1RA to a basal insulin

Watch and download these resources to assist you in starting Toujeo Solostar in a patient currently prescribed a GLP-1RA for whom insulin might be an option.

Medical supervision with close metabolic monitoring is recommended during any switch of therapy or initiation of insulin, and in the initial weeks thereafter.

Start and Switch Guide

Download this summary guide on how to start or switch diabetes patients to Toujeo.

Access Patient Materials

Print and distribute this card for your patient to enable an easy access to support materials.

Checklist for starting Toujeo

Download this aid memoir developed by Anne Goodchild to support your initiation.

Once Daily GLP-1 to Toujeo

Anne Goodchild (DSN and Lead Trainer for PITStop) shares guidance and practical recommendations and tips of how she would transition a patient with T2DM moving from a daily GLP-1 to Toujeo SoloStar.

This includes DVLA guidance, navigating your way through NICE and other things to consider such as OAD and therapy injection sites.

Once Weekly GLP-1 to Toujeo

PITStop lead coach and DSN, Anne Goodchild, shares guidance and recommendations on how to transition patients with Type 2 diabetes from a weekly GLP-1 to Toujeo SoloStar.

Anne shares practical advice and DVLA guidelines, navigating NICE guidelines and other things to think about like OAD therapy and injection sites.

If GLP-1s are not suitable

Guidance and practical recommendations for transitioning T2DM patients who are insulin naive to Toujeo SoloStar.

This includes DVLA and NICE guidance and other things to consider such as OAD therapy and injection sites.

How to Order Toujeo?

Presentation

PIP Code

Toujeo NHS list price

Toujeo® SoloSTAR®
Pre-filled disposable pen; 450 units of insulin

GB Pack size: 3 x 1.5 ml
NI Pack size: 5 x 1.5 ml

3981354

GB: £32.14

NI: £53.57

Toujeo® DoubleSTAR®
Pre-filled disposable pen; 900 units of insulin

GB Pack size: 3 x 3 ml
NI Pack size: 3 x 3 ml

4104782

GB: £64.27

NI: £64.27

Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day.

There are two channels through which you can order Toujeo.

Via AAH:

  • Community Pharmacy - 0344 561 8899
  • Dispensing Doctors - 0344 561 8899
  • Hospitals - 0344 561 6699

Via Phoenix:

  • 01928 750 500 / 01928 750 750

If you are having any issues in getting stock of Toujeo from the above wholesalers, in that instance please contact Sanofi Customer Service on 0800 854 430 for further support.

Toujeo Features

Toujeo® can give your patients sustained glycaemic control when administered once daily in the morning or evening*1

Study Design

Toujeo® can give your patients flexibility around their injection time to fit in with their daily lives when needed*†1

The pen that was rated by 97.5% of adult patients as easy to use‡5

The highest unit capacity of any basal insulin pen on the market1-5

1/4

Toujeo® can give your patients sustained glycaemic control when administered once daily in the morning or evening*1

Study Design

Toujeo® can give your patients flexibility around their injection time to fit in with their daily lives when needed*†1

The pen that was rated by 97.5% of adult patients as easy to use‡5

The highest unit capacity of any basal insulin pen on the market1-5

1/2

Expert Videos

Get in touch with the Diabetes Team

Diabetes Products

MAT-XU-2302426 (v11.0) Date of Preparation: April 2024